These are troubled times for Merck
Back in October, Merck announced that it would eliminate 4,400 jobs. By the end of the year, it had whacked 3,200, taking a $195 million charge in the process. The company expects additional restructuring costs in 2004, with total annual cost savings of $250 million to $300 million starting in 2005.
For the quarter, sales of Zocor -- the company's cholesterol drug -- fell 30% to $1.21 billion, hurt by increased competition as well as the loss of patent protection outside the U.S. Sales of arthritis treatment Vioxx, on the other hand, almost doubled to $731 million.
At about 15 times 2004 earnings, Merck looks interesting. The question is how the second-largest U.S. drug maker will replace Zocor's $5 billion in annual sales when the drug comes off patent in 2006. It's a question that looms large in the wake of a series of late-stage failures.
But like rivals Pfizer
Will replacing Zocor's $5 billion in annual sales be easy? No. But for a company of such size and resources, Merck in the mid-40s is tempting. If nothing else, there doesn't seem to be a whole lot of risk baked in at these levels.
Give us your take on the Merck discussion board.
Jeff Hwang can be reached here.
More from The Motley Fool
Alcoa (AA) Q4 2017 Earnings Conference Call Transcript
AA earnings call for the period ending December 31, 2017.
Are Tax-Free Municipal Bonds Right for You?
The short answer: It depends on your risk tolerance and investment goals.
Why the Apple Inc. MacBook Pro Won't See a Major Upgrade in 2018
This supply chain report is probably right on the money.